AI Maverick Intel Inc. (OTC: AIMV) has entered into a Right of First Refusal Agreement with HEAL Group Holdings Inc., granting the company exclusive review and matching rights for third-party offers on specific HEAL assets or business units. The agreement, effective February 11, 2026, provides AI Maverick Intel with potential acquisition access to HEAL's portfolio of artificial intelligence-driven healthcare technology and services operating in more than six countries.
In exchange for these rights, AI Maverick Intel will issue 120 million common shares to HEAL at a deemed price of $0.02 per share, representing total consideration of $2.4 million. The arrangement will remain in place for three years unless terminated earlier by mutual agreement between the two companies. This strategic move positions AI Maverick Intel to potentially expand its footprint in the rapidly growing healthcare technology sector, where AI applications are increasingly transforming patient care, diagnostics, and operational efficiency.
The importance of this agreement lies in its timing and strategic positioning within the healthcare technology landscape. As artificial intelligence continues to revolutionize healthcare delivery globally, companies with access to established AI healthcare platforms gain significant competitive advantages. The right of first refusal provides AI Maverick Intel with a structured pathway to evaluate and potentially acquire proven technologies without immediate capital expenditure, while securing preferential access to assets that might otherwise become unavailable to competitors.
For investors and industry observers, this agreement represents a calculated approach to growth in a sector experiencing substantial investment and innovation. The healthcare AI market has been expanding rapidly as providers seek solutions to improve patient outcomes, reduce costs, and address workforce challenges. By securing these rights, AI Maverick Intel positions itself to capitalize on emerging opportunities while mitigating acquisition risks through the structured evaluation process. The company's focus on identifying opportunities at the intersection of artificial intelligence, data platforms, and emerging technology-enabled industries aligns directly with HEAL Group's healthcare technology portfolio.
The broader implications extend to healthcare providers and patients who may benefit from accelerated technology adoption if AI Maverick Intel exercises its rights and invests in further development of these platforms. The arrangement also highlights the increasing convergence between traditional technology companies and specialized healthcare solution providers, a trend likely to continue as digital transformation reshapes the medical industry globally. Additional information about AI Maverick Intel is available in the company's newsroom at http://ibn.fm/AIMV, while the full press release detailing this agreement can be viewed at https://ibn.fm/7LS0i.
